Pancreatic Cancer Research

ResearcherYonsei UniversityActive in the last 2 years

Ho Kyoung Hwang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4064-7776; OpenAlex author ID A5042270068, A5065349135. Sources: OpenAlex.

Their work

Papers
74 (first author 17, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
105
Papers, trials and grants by year

2012: 2 papers · 2013: 3 papers · 2014: 1 paper · 2015: 2 papers · 2016: 6 papers · 2017: 8 papers · 2018: 5 papers · 2019: 5 papers · 2020: 10 papers · 2021: 7 papers · 2022: 9 papers · 2023: 1 paper · 2024: 5 papers · 2025: 5 papers · 2026: 5 papers

Papers 50 of 74

  1. Comparison of Long-Term Oncologic and Perioperative Outcomes of Minimally Invasive and Open Pancreatoduodenectomy for Resectable and Borderline Resectable Panc… Co-author DOI 10.1002/jhbp.70063↗
  2. Feasibility and safety of minimally invasive distal pancreatosplenectomy in resectable and borderline resectable pancreatic cancer following neoadjuvant chemot… First author DOI 10.1007/s00464-025-12533-3↗
  3. Long-term oncologic outcomes and prognostic factors in resected stage IA pancreatic cancer: a retrospective cohort study. First author DOI 10.1007/s00464-026-12646-3↗
  4. Prospective Evaluation of Irreversible Electroporation With Clustered Electrodes as a Novel Palliative Approach for Locally Advanced Pancreatic Cancer. Co-author DOI 10.3348/kjr.2025.1394↗
  5. Development of an artificial intelligence-based prediction platform for early recurrence of resectable pancreatic cancer after curative surgery-toward future u… Co-author DOI 10.4174/astr.2026.110.2.76↗
  6. Perioperative Clinical Usage of Phellinus Linteus as a Nutraceutical for Non-FOLFIRINOX-Based Postoperative Adjuvant Chemotherapy for Resected Pancreatic Cance… Co-author DOI 10.1177/15347354251353499↗
  7. Optimal Number of Lymph Nodes Retrieved to Lower the Risk of False N0 for Patients with Pancreatic Cancer Undergoing Curative Surgery. Co-author DOI 10.1245/s10434-025-18029-7↗
  8. Is There a Potential Oncologic Role for Local Therapy on Hepatic Metastasis in Patients Who Undergo Curative Pancreatectomy for Pancreatic Cancer? Co-author DOI 10.3349/ymj.2024.0078↗
  9. Immediate Postoperative AbnobaVISCUM® F as an Adjuvant Treatment in Patients Receiving Standard Care after Pancreatic Cancer Resection. Co-author DOI 10.3349/ymj.2024.0493↗
  10. Stromal secreted protein acidic and rich in cysteine expression: A potential target for improved prognosis in patients with pancreatic cancer. Co-author DOI 10.4251/wjgo.v17.i11.110704↗
  11. Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/cam4.70363↗
  12. Integrative analysis of spatial and single-cell transcriptome data from human pancreatic cancer reveals an intermediate cancer cell population associated with … Co-author DOI 10.1186/s13073-024-01287-7↗
  13. Deep-Transfer-Learning-Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting Survival of Patients With Pancreatic Ca… Co-author DOI 10.1200/cci.24.00021↗
  14. Correlation between Angiotensin Inhibitor Administration and Longer Survival in Patients Who Underwent Curative Resection for Pancreatic Cancer. Last author DOI 10.3349/ymj.2023.0399↗
  15. Glucose-to-Lymphocyte Ratio (GLR) as an Independent Prognostic Factor in Patients with Resected Pancreatic Ductal Adenocarcinoma-Cohort Study. Co-author DOI 10.3390/cancers16101844↗
  16. Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database. Co-author DOI 10.1002/jhbp.1316↗
  17. Combined tumor epithelial and stromal histopathology with keratin 81 expression predicts prognosis for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.1025↗
  18. Comparison of oncologic outcomes between open and laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma using data from the KOTUS-BP national… Co-author DOI 10.1016/j.hpb.2022.01.012↗
  19. Systemic inflammation response index correlates with survival and predicts oncological outcome of resected pancreatic cancer following neoadjuvant chemotherapy. Co-author DOI 10.1016/j.pan.2022.08.009↗
  20. Regional lymph node metastasis detected on preoperative CT and/or FDG-PET may predict early recurrence of pancreatic adenocarcinoma after curative resection. Co-author DOI 10.1038/s41598-022-22126-y↗
  21. Neoadjuvant FOLFIRINOX Followed by Pancreatoduodenectomy for Pancreatic Cancer in Patients with Previous Transhiatal Esophagectomy for Esophageal Cancer. Co-author DOI 10.1159/000525294↗
  22. Laparoscopic radical distal pancreatosplenectomy with celiac axis excision following neoadjuvant chemotherapy for locally advanced pancreatic cancer. Co-author DOI 10.14701/ahbps.21-097↗
  23. Laparoscopic distal pancreatosplenectomy for left-sided pancreatic cancer in patients with radical subtotal gastrectomy for gastric cancer. Co-author DOI 10.14701/ahbps.22-016↗
  24. Should the Splenic Vein Be Preserved-Fate of Sinistral Portal Hypertension after Pancreatoduodenectomy with Vascular Re-Section for Pancreatic Cancer. Co-author DOI 10.3390/cancers14194853↗
  25. Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis. Co-author DOI 10.5009/gnl20301↗
  26. MCT4 as a potential therapeutic target to augment gemcitabine chemosensitivity in resected pancreatic cancer. First author DOI 10.1007/s13402-021-00643-8↗
  27. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2021.103218↗
  28. Usefulness of artificial intelligence for predicting recurrence following surgery for pancreatic cancer: Retrospective cohort study. Co-author DOI 10.1016/j.ijsu.2021.106050↗
  29. Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers. First author DOI 10.1016/j.pan.2021.02.007↗
  30. Initial experience of irreversible electroporation for locally advanced pancreatic cancer in a Korean population. Co-author DOI 10.1177/0284185120917118↗
  31. Tumor-Specific miRNA Signatures in Combination with CA19-9 for Liquid Biopsy-Based Detection of PDAC. Co-author DOI 10.3390/ijms222413621↗
  32. Laparoscopic pancreaticoduodenectomy in pancreatic ductal adenocarcinoma. Co-author DOI 10.7602/jmis.2021.24.3.169↗
  33. Unexpected Para-aortic Lymph Node Metastasis in Pancreatic Ductal Adenocarcinoma: a Contraindication to Resection? First author DOI 10.1007/s11605-019-04483-8↗
  34. Oncologic impact of preoperative prognostic nutritional index change in resected pancreatic cancer following neoadjuvant chemotherapy. First author DOI 10.1016/j.pan.2019.12.006↗
  35. Oncologic Impact of Local Recurrence in Resected Pancreatic Cancer and Topographic Preference in Local Recurrence Patterns According to Tumor Location. Co-author DOI 10.1097/mpa.0000000000001679↗
  36. Preoperative prediction of futile surgery in patients with radiologically resectable or borderline resectable pancreatic adenocarcinoma. Co-author DOI 10.1111/jgh.14837↗
  37. Feasibility and Safety of Laparoscopic Radical Distal Pancreatosplenectomy with Adrenalectomy in Advanced Pancreatic Cancer. First author DOI 10.1245/s10434-020-08670-9↗
  38. Laparoscopic repeated pancreatectomy for isolated local recurrence in remnant pancreas following laparoscopic radical pancreatectomy for pancreatic ductal aden… Co-author DOI 10.14701/ahbps.2020.24.4.542↗
  39. A nomogram to preoperatively predict 1-year disease-specific survival in resected pancreatic cancer following neoadjuvant chemoradiation therapy. Co-author DOI 10.21147/j.issn.1000-9604.2020.01.12↗
  40. Yonsei Criteria, a Potential Linkage to Intratumoral Foxp3⁺/CD8⁺ Ratio for the Prediction of Oncologic Outcomes in Resected Left-Sided Pancreatic Cancer. Co-author DOI 10.3349/ymj.2020.61.4.291↗
  41. Intraoperative Transfusion is Independently Associated with a Worse Prognosis in Resected Pancreatic Cancer-a Retrospective Cohort Analysis. Co-author DOI 10.3390/jcm9030689↗
  42. Repeated Pancreatectomy for Isolated Local Recurrence in the Remnant Pancreas Following Radical Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Pooled A… Co-author DOI 10.3390/jcm9123945↗
  43. Developing a preoperative serum metabolome-based recurrence-predicting nomogram for patients with resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-019-55016-x↗
  44. Association of preoperative total lymphocyte count with prognosis in resected left-sided pancreatic cancer. First author DOI 10.1111/ans.15030↗
  45. Potential Impact of Phellinus linteus on Adherence to Adjuvant Treatment After Curative Resection of Pancreatic Ductal Adenocarcinoma: Outcomes of a Propensity… First author DOI 10.1177/1534735418816825↗
  46. Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer: A pilot study. Co-author DOI 10.3233/cbm-181847↗
  47. Preoperative Metabolic Tumor Volume2.5 Associated with Early Systemic Metastasis in Resected Pancreatic Cancer: A Transcriptome-Wide Analysis. First author DOI 10.5009/gnl18242↗
  48. Tumor-Targeting Salmonella typhimurium A1-R Promotes Tumoricidal CD8+ T Cell Tumor Infiltration and Arrests Growth and Metastasis in a Syngeneic Pancreatic-Can… Co-author DOI 10.1002/jcb.26224↗
  49. Different biological behaviors in left-sided pancreatic cancer according to Yonsei criteria: Proposal of a modified Yonsei criteria score. Co-author DOI 10.1016/j.pan.2018.09.001↗
  50. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. Co-author DOI 10.1016/j.tice.2018.05.003↗

Closest collaborators

The 25 strongest of 105 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chang Moo Kang · 62 shared papers, 2012–2026 · strength 8.89
  2. Woo Jung Lee · 47 shared papers, 2012–2025 · strength 5.58
  3. Sung Hyun Kim · 20 shared papers, 2016–2026 · strength 4.56
  4. Seung Soo Hong · 12 shared papers, 2020–2026 · strength 3.39
  5. Seungmin Bang · 12 shared papers, 2013–2026 · strength 1.51
  6. Munseok Choi · 7 shared papers, 2020–2026 · strength 1.42
  7. Sung Hwan Lee · 14 shared papers, 2014–2021 · strength 1.39
  8. Seoung Yoon Rho · 7 shared papers, 2018–2026 · strength 1.26
  9. Moon Jae Chung · 8 shared papers, 2013–2026 · strength 1.08
  10. Seung‐seob Kim · 6 shared papers, 2022–2024 · strength 1.05
  11. Hee Seung Lee · 7 shared papers, 2020–2024 · strength 0.95
  12. Jin Seok Heo · 5 shared papers, 2021–2026 · strength 0.91
  13. Jeong Youp Park · 8 shared papers, 2012–2024 · strength 0.87
  14. Mi‐Suk Park · 5 shared papers, 2021–2024 · strength 0.78
  15. Seung Woo Park · 6 shared papers, 2013–2024 · strength 0.71
  16. Si Young Song · 8 shared papers, 2012–2024 · strength 0.68
  17. Jung Hyun Jo · 5 shared papers, 2020–2024 · strength 0.68
  18. In Woong Han · 3 shared papers, 2023–2026 · strength 0.65
  19. Jae Uk Chong · 5 shared papers, 2017–2025 · strength 0.65
  20. Hongbeom Kim · 3 shared papers, 2022–2026 · strength 0.65
  21. Hye Yeon Yang · 2 shared papers, 2024–2025 · strength 0.56
  22. Ji Su Kim · 3 shared papers, 2020–2022 · strength 0.53
  23. So Jeong Yoon · 2 shared papers, 2025–2026 · strength 0.53
  24. Sang Hyun Shin · 2 shared papers, 2025–2026 · strength 0.53
  25. Choong‐kun Lee · 3 shared papers, 2022–2024 · strength 0.52

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.